• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Rheumatology

Show Search
Hide Search
  • About Us
    • Our History
    • Our Faculty
    • Rheumatology Fellowship
    • Administrative Core
    • Contact Us
    • eNews Signup
  • Make an Appointment
    • Clinic Information
    • Specialty Clinics
  • Our Research
    • Current Research Studies
    • Andrade Lab
    • Darrah Lab
    • Konig Lab
    • Rosen Casciola Lab
    • RDRCC
    • Bayview Immunomics Core (BIC)
  • Charitable Giving
    • Dr. John Welton Fellowship in Rheumatology
    • Dr. Ira T. Fine Discovery Fund
    • Dr. Nadia D. Morgan Memorial Fund
  • News
    • LEAP Magazine
  • Education
    • Advances in the Diagnosis and Treatment of the Rheumatic Diseases Course
    • RheumTV – Patient Education Video Library
Home / News / Research / Pneumocystis jiroveci pneumonia is a rare but serious complication for patients with rheumatic diseases

Pneumocystis jiroveci pneumonia is a rare but serious complication for patients with rheumatic diseases

March 1, 2017 By Erika Darrah

[arve url=”https://vimeo.com/208891399″ /]

Summary

A research team from the Johns Hopkins Division of Rheumatology lead by Christopher Mecoli, M.D., M.H.S, studied medical records of patients with rheumatic diseases who were admitted to the Johns Hopkins Hospital for pneumocystis jiroveci pneumonia (PJP) infection over a 20-year period (1996-2015). PJP is an uncommon but severe lung infection that can occur in patients with rheumatic disease, in particular in those who are taking medications that suppress the immune system.

Why was this study done?

Although PJP infection is rare, it can be deadly. This is especially important in people with compromised immune systems, including those with rheumatic diseases on immunosuppressive therapies. It is known from the literature that people taking more than 20mg of prednisone daily for over 4 weeks are at increased risk for this severe infection and are recommended to take preventative therapy (prophylaxis). However, there is little data available from a single hospital to understand the prevalence of PJP and impact of medications in patients with rheumatic diseases. In this study, the authors sought to identify which rheumatic diseases, medications and doses were most associated with developing PJP. In addition, this study determined the trend in PJP seen among patients with rheumatic disease over a 20-year period at the Johns Hopkins Hospital.

How was this study done?

The authors conducted a historical review of all admitted patients to the Johns Hopkins Hospital who received a diagnosis of PJP and had an underlying diagnosis of a rheumatic disease from 1996-2016. They described the clinical characteristics of these patients including their medications, doses, and white cell count as well as their mortality rate.

What were the major findings?

Twenty-one cases of confirmed PJP in patients with rheumatic diseases were identified over the 20-year period, averaging one case per year. The most common underlying rheumatologic conditions found in these patients were inflammatory myopathy, lupus, and granulomatosis with polyangiitis. None of these 21 patients were receiving prophylaxis for PJP upon admission. Eighteen (86%) were receiving more than 20 mg prednisone daily at the time of PJP diagnosis, which was previously shown to increase the risk of PJP infection in other patient groups. However, 3 additional people with PJP were treated with less than 20 mg prednisone, but all received treatment with additional immunosuppressive medications including cyclophosphamide. Overall, there was a 43% (9/21) mortality rate among these patients following PJP infection. The use of additional immunosuppressive medications, presence of documented lung disease, or low white blood cell count did not predict the outcome of these patients.

What is the impact of this work?

PJP infection is associated with a high mortality rate yet is a largely preventable complication of rheumatic disease treatment. Physicians should consider initiating prophylaxis to protect against PJP infection for patients exceeding the daily 20 mg prednisone threshold, and those receiving cyclophosphamide. The impact of the duration of therapy was not studied in this review and is an important variable to consider in future studies since patients with rheumatic diseases can receive long-term treatment with immunosuppressive drugs.

Link to original research article:

Pneumocystis jiroveci pneumonia in rheumatic disease: a 20-year single-centre experience. Mecoli CA, Saylor D, Gelber AC, Christopher-Stine L. Clin Exp Rheumatol. 2017 Jan 27

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Filed Under: Research

Erika Darrah

Erika Darrah, Ph.D. is an Assistant Professor of Medicine in the Johns Hopkins University Division of Rheumatology with an interest understanding the mechanisms that drive the development of rheumatic diseases.

Use of this Site

All information contained within the Johns Hopkins Division of Rheumatology website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

Rheumatology News

  • News
  • Promotions

Recent News

LEAP – Winter 2023: Big Data, Individualized Care

February 23, 2023

LEAP Rounds – Holiday 2022

November 9, 2022

Dr. Rachel Wallwork named ACR Distinguished Fellow

October 19, 2022

RheumTV Logo

Rheum.TV is an educational platform created to help patients living with a rheumatic disease. With over 100 disease education videos produced by the team at Johns Hopkins Rheumatology.

Visit RheumTV

Footer

Rheumatology Specialty Care Centers

  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center
  • Johns Hopkins Vasculitis Center

Connect with Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2023 Johns Hopkins Rheumatology - Patient Privacy